Janik Rafal, Thomason Lynsie A M, Chaudhary Simone, Dorr Adrienne, Scouten Amy, Schwindt Graeme, Masellis Mario, Stanisz Greg J, Black Sandra E, Stefanovic Bojana
Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
Biochim Biophys Acta. 2016 May;1862(5):957-65. doi: 10.1016/j.bbadis.2015.10.023. Epub 2015 Oct 28.
Despite the growing recognition of the significance of cerebrovascular impairment in the etiology and progression of Alzheimer's disease (AD), the early stage brain vascular dysfunction and its sensitivity to pharmacological interventions is still not fully characterized. Due to the early and aggressive treatment of probable AD with cholinesterase inhibitors (ChEI), which in and of themselves have direct effects on brain vasculature, the vast majority of hemodynamic measurements in early AD subjects reported hitherto have consequently been made only after the start of treatment, complicating the disentanglement of disease- vs. treatment-related effects on the cerebral vasculature. To address this gap, we used pseudo continuous arterial spin labeling MRI to measure resting perfusion and visual stimulation elicited changes in cerebral blood flow (CBF) and blood oxygenation dependent (BOLD) fMRI signal in a cohort of mild AD patients immediately prior to, 6months post, and 12months post commencement of open label cholinesterase inhibitor treatment. Although patients exhibited no gray matter atrophy prior to treatment and their resting perfusion was not distinguishable from that in age, education and gender-matched controls, the patients' visual stimulation-elicited changes in BOLD fMRI and blood flow were decreased by 10±4% (BOLD) and 23±2% (CBF), relative to those in controls. Induction of cholinesterase inhibition treatment was associated with a further, 7±2% reduction in patients' CBF response to visual stimulation, but it stabilized, at this new lower level, over the follow-up period. Likewise, MMSE scores remained stable during the treatment; furthermore, higher MMSE scores were associated with higher perfusion responses to visual stimulation. This study represents the initial step in disentangling the effects of AD pathology from those of the first line treatment with cholinesterase inhibitors on cerebral hemodynamics and supports the use of arterial spin labeling MRI for quantitative evaluation of the brain vascular function in mild Alzheimer's disease. The findings provide evidence of a pronounced deficit in the visual cortex hyperemia despite the relative sparing of visual function in early stage AD, its reduction with ChEI treatment induction, and its stabilization in the first year of cholinesterase inhibition treatment. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.
尽管人们越来越认识到脑血管损伤在阿尔茨海默病(AD)病因和进展中的重要性,但早期脑血管功能障碍及其对药物干预的敏感性仍未得到充分表征。由于对可能的AD使用胆碱酯酶抑制剂(ChEI)进行早期积极治疗,而这些药物本身对脑血管有直接影响,因此迄今为止报道的早期AD患者的绝大多数血流动力学测量仅在治疗开始后进行,这使得区分疾病与治疗对脑血管的影响变得复杂。为了填补这一空白,我们使用伪连续动脉自旋标记MRI来测量一组轻度AD患者在开放标签胆碱酯酶抑制剂治疗开始前、治疗后6个月和12个月时的静息灌注以及视觉刺激引起的脑血流量(CBF)变化和血氧依赖性功能磁共振成像(BOLD)信号。尽管患者在治疗前没有灰质萎缩,且其静息灌注与年龄、教育程度和性别匹配的对照组无差异,但与对照组相比,患者视觉刺激引起的BOLD fMRI和血流变化分别降低了10±4%(BOLD)和23±2%(CBF)。胆碱酯酶抑制治疗的诱导与患者对视觉刺激的CBF反应进一步降低7±2%有关,但在随访期间,该反应稳定在这个新的较低水平。同样,MMSE评分在治疗期间保持稳定;此外,较高的MMSE评分与对视觉刺激的较高灌注反应相关。本研究是区分AD病理与胆碱酯酶抑制剂一线治疗对脑血流动力学影响的第一步,并支持使用动脉自旋标记MRI对轻度阿尔茨海默病的脑血管功能进行定量评估。研究结果提供了证据,表明尽管早期AD患者的视觉功能相对保留,但视觉皮层充血存在明显缺陷,ChEI治疗诱导后充血减少,并在胆碱酯酶抑制治疗的第一年保持稳定。本文是名为:血管对认知障碍和痴呆的影响的特刊的一部分,由M. Paul Murphy、Roderick A. Corriveau和Donna M. Wilcock编辑。